Pharmaceutical CDMO Market To Reach $232.587 Billion By 2030

The global Pharmaceutical CDMO Market size is expected to reach USD 232.587 billion by 2030, registering a CAGR of 6.1% over the forecast period, according to a new report by Grand View Research, Inc. increasing demand for biologics, growing outsourcing of drug development and manufacturing activities, and rising investments in research and development (R&D) by pharmaceutical and biotechnology companies as key drivers of market growth. Additionally, the report highlights the emergence of small and mid-sized pharma and biotech companies and the shift towards personalized medicine as further factors expected to drive the market forward.

The rising demand for biologics, in particular is anticipated to significantly contribute to the expansion of the CDMO industry. The use of these complex molecules created by living things in the treatment of many ailments is becoming more and more crucial. Because many pharmaceutical and biotechnology companies lack the specific manufacturing capabilities needed for biologics, medication research, and manufacturing processes are increasingly being outsourced. Pharmaceutical and biotech firms are turning to CDMOs to assist lower costs and increase efficiency as the cost of drug development and production keeps rising.

The market for CDMOs is expanding because of a number of developments, including the expansion of small and mid-sized pharma and biotech firms, the trend toward personalized medicine, and the rising need for biologics. The COVID-19 pandemic provides a recent illustration of the demand for CDMO services. Several businesses lack the specific knowledge and manufacturing capabilities needed to develop and produce COVID-19 vaccines and treatments. As a result, some pharmaceutical firms have enlisted CDMOs' assistance in the development and manufacturing of vaccines and treatments.

For instance, Moderna, a biotech company, partnered with Lonza, a CDMO, to manufacture its COVID-19 vaccine. This partnership allowed Moderna to significantly increase its manufacturing capacity and produce millions of vaccine doses in a short amount of time, helping to address the urgent need for COVID-19 vaccines. This example highlights the important role that CDMOs play in drug development and manufacturing and how they are helping to address critical global health challenges.

Related Press Release@ Pharmaceutical CDMO Market Report

Pharmaceutical CDMO Market Report Highlights

• API holds the largest revenue share and fastest CAGR in 2022, primarily due to its crucial role as the primary component of any formulated drug. The lack of skilled expertise and inadequate manufacturing capacity are driving CDMOs and CMOs to invest heavily in the expansion of API manufacturing capacities
• The commercial segment dominated the CDMO market in 2022, driven by the increasing demand for generic drugs and the approval of numerous regenerative medications and other biologic treatments. These factors are fueling the demand for commercial drug CDMO services
• Due to the rising global incidence of cancer, the oncology category is dominating the CDMO market with a sizable revenue share and the quickest growth rate. Since cancer is the largest cause of death worldwide, there will likely be an increase in the demand for innovative cancer therapies, which will present opportunities for the CDMO and pharmaceutical industries. Oncology drug development in the pharmaceutical sector is expected to have a major impact on revenue
• Asia Pacific dominated the market with the largest market share and fastest growth rate in 2022, mainly driven by India and China's favorable legislation and significantly low production costs. The region continues to be the leading market for contract development and manufacturing organizations. While China and India are the leading providers of API manufacturing, the United States remains the main outsourcing hub for pharmaceutical development 

Related Reports@

Nutraceuticals CDMO Market

Healthcare Contract Development And Manufacturing Organization Market

Pharmaceutical CDMO Market Segmentation

Grand View Research has segmented the global pharmaceutical CDMO market based on product, workflow, application, and region:

Pharmaceutical CDMO Product Outlook (Revenue, USD Million, 2018 - 2030)

• API
• By Synthetic

• Solid
• Liquid
• By Type
• Traditional Active Pharmaceutical Ingredient (Traditional API)
• Highly Potent Active Pharmaceutical Ingredient (HP-API)
• Antibody Drug Conjugate (ADC)
• Others
• By Drug
• Innovative
• Generics
• By Manufacturing
• Continuous Manufacturing
• Batch Manufacturing
• Biotech
• Drug Product
• Oral Solid Dose
• Semi-solid dose
• Liquid Dose
• Others

Pharmaceutical CDMO Workflow Outlook (Revenue, USD Million, 2018 - 2030)

• Clinical
• Commercial

Pharmaceutical CDMO Application Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology
• Hormonal
• Glaucoma
• Cardiovascular Disease
• Diabetes
• Others

Pharmaceutical CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• U.S.                
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com